ArticleOncogene2026
M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.
Shinkichi Takamori et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleOncogene2026
Shinkichi Takamori et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.